Skip to main content

Publications: secondary analysis for MA5, PA6, CE6, CLC2, CRC6, CO17

Publication: PA6, CE6, CLC2, CRC6, CO17
MA5:
Jensen M-B, Nielsen TO, Bartlett J, Lænkholm A-V, Shepherd L, Ejlertsen B. Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer. npj Breast Cancer 11: 26. 2025.
 
PA6:
Fraunhoffer N, Hammel P, Conroy T, Nicolle R, Bachet JB, Harlé A, Rebours V, Turpin A, Ben Abdelghani M, Mitry E, Biagi J, Chanez B, Bigonnet M, Lopez A, Evesque L, Lecomte T, Assenat E, Bouché O, Renouf DJ, Lambert A, Monard L, Mauduit M, Cros J, Iovanna J, Dusetti N. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Annals of Oncology 35: 780-791. 2024.
 
Lambert A, Salleron J, Harlé A, Biagi JJ, Leroux A, Thomas J, Monard L, Cros J, Marchal F, Ayav A, Conroy T. Impact of Positive Resection Margins on Recurrence and Survival Following Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG PA-6 Randomized Controlled Trial (ONLINE). Annals of Surgery 2024.
 
CE6:
Malmström A, Oppong FB, O`Callaghan CJ, Wick W, Laperriere N, Gorlia T, Weller M, Henriksson R, Mason W, Platten M, Cantagallo E, Grønberg BH, Reifenberger G, Marosi C, Perry JR, NCBTSG N, CCTG, Group EBT. Prognostic factors for overall survival in elderly patients with glioblastoma: Analysis of the pooled NOA-08 and Nordic trials with the CCTG-EORTC (CE.6) trial. Neuro-Oncology Advances 6: vdae211. 2024.
CLC2: updated analysis
Woyach JA, Perez Burbano G, Ruppert AS, Miller C, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly J, Nattam S, Larson RA, Erba H, Litzow M, Luger S, Owen C, Kuzma C, Abramson JS, Little RF, Dinner S, Stone RM, Uy G, Stock W, Mandrekar SJ, Byrd JC. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood 143: 1616-1627. 2024.
CRC6: nested cohort
Brown JC, Ma C, Shi Q, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi S, Chang V, Goldberg RM, O’Reilly EM, Shields AF, Meyerhardt JA. Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B–Southwest Oncology Group 80702 (Alliance). JNCI: Journal of the National Cancer Institute 116: 2032-2039. 2024.
CO17:
Karapetis CS, Liu H, Sorich MJ, Pederson LD, Van Cutsem E, Maughan T, Douillard JY, O’Callaghan CJ, Jonker D, Bokemeyer C, Sobrero A, Cremolini C, Chibaudel B, Zalcberg J, Adams R, Buyse M, Peeters M, Yoshino T, de Gramont A, Shi Q. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. British Journal of Cancer 130: 1269-1278. 2024.